Overview

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery

Status:
Completed

Trial end date:
2009-10-01

Target enrollment:

Participant gender:

Summary

The primary objective was to compare the efficacy of once daily [q.d] subcutaneous [s.c.] injections of Semuloparin sodium (AVE5026) with q.d. s.c. injections of Enoxaparin for the prevention of Venous Thromboembolic Events [VTE] in patients undergoing hip fracture surgery. The secondary objectives were to evaluate the safety of AVE5026 in patients undergoing hip fracture surgery, and to document AVE5026 exposure in this population.

Phase:

Phase 3

Details

Lead Sponsor:

Sanofi

Treatments:

Enoxaparin
Enoxaparin sodium
Heparin, Low-Molecular-Weight
Semuloparin